Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2687669 | 1.00 | TP53 (0.32) | TP53 | |
| SCHEMBL2686923 | 1.00 | TP53 (0.32) | TP53 | |
| SCHEMBL1369677 | 0.82 | — | — | |
| SCHEMBL13413224 | 0.82 | — | — | |
| SCHEMBL13413222 | 0.82 | — | — | |
| SCHEMBL25176906 | 0.80 | APLNR (0.31) | — | |
| SCHEMBL19260399 | 0.80 | — | — | |
| SCHEMBL15717701 | 0.80 | APLNR (0.31) | — | |
| SCHEMBL8221420 | 0.80 | APLNR (0.31) | — | |
| SCHEMBL8823309 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665454-A1 | IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250304523-A1 | COMBINED LACTATE AND KETONE BODY ESTERS FOR MEDICAL AND NUTRITIONAL USE | AARHUS UNIVERSITET (DK) | 2025-10-02 | — | — | US | disclosed |
| US-20250283066-A1 | METHODS AND COMPOSITIONS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-09-11 | — | — | US | disclosed |
| EP-4583867-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12331058-B2 | SHP2 and CDK4/6 dual-target inhibitory compound and pharmaceutical composition containing the same | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-06-17 | — | — | US | disclosed |
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC | 2025-05-15 | — | — | US | disclosed |
| US-12286657-B2 | Methods and compositions | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-04-29 | — | — | US | disclosed |
| EP-4519239-A1 | COMBINED LACTATE AND KETONE BODY ESTERS FOR MEDICAL AND NUTRITIONAL USE | Aarhus Universitet (DK) | 2025-03-12 | — | — | EP | disclosed |
| WO-2025029890-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20250026756-A1 | SHP2 AND CDK4/6 DUAL-TARGET INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-01-23 | — | — | US | disclosed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994013687-A1 | PYRIMIDINE NUCLEOTIDE PRECURSORS FOR TREATMENT OF SYSTEMIC INFLAMMATION AND INFLAMMATORY HEPATITIS | PRO-NEURON, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0570519-A1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO-NEURON, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
| EP-0339075-B1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
| CN-1071577-A | Handle the toxicity of chemotherapy reagent and Anti-virus agent with acylated pyrimidine nucleosides | PRO NEURON INC (US) | 1993-05-05 | — | — | CN | disclosed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | disclosed |
| WO-1992013561-A1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO-NEURON, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| EP-0355131-A1 | ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF | PRO-NEURON, INC. (US) | 1990-02-28 | — | — | EP | disclosed |
| EP-0339075-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | SCN8A, TRPV1, SCNN1A | TP53 4831/4885 |
| US-12286657-B2 | Methods and compositions | TRMT1, TARBP1, RNGTT | TP53 1820/4885 |
| US-20250304523-A1 | COMBINED LACTATE AND KETONE BODY ESTERS FOR MEDICAL AND NUTRITIONAL USE | LDHB, LDHA, LCT | TP53 1240/4885 |
| US-20250026756-A1 | SHP2 AND CDK4/6 DUAL-TARGET INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DUSP6, DUSP4, DUSP1 | TP53 254/4885 |
| US-20250283066-A1 | METHODS AND COMPOSITIONS | TRMT1, TARBP1, RNGTT | TP53 1820/4885 |
| US-12331058-B2 | SHP2 and CDK4/6 dual-target inhibitory compound and pharmaceutical composition containing the same | DUSP6, DUSP4, DUSP1 | TP53 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.